Alan Jakimo, JD
Senior Public Policy Fellow Regenerative Medicine Foundation
Alan L. Jakimo advises companies in the life science and information technology sectors. These companies range in size from start-up to multinational. In life science, he advises companies along a spectrum that includes both pharmaceuticals and medical devices. In the information technology sector, he has been involved in many transactions lying in that sector’s intersection with life science and health care, with growing attention on the application to life science and health care of various types of artificial intelligence. From 2017 through 2022, he served as an investment banker; and prior to that, he spent three decades as a partner at Sidley Austin LLP and one of its predecessors, where his practice covered a range of transaction-oriented disciplines, including securities and venture capital finance, mergers and acquisitions, collaborative development of novel technologies, licensing and intellectual property, and pharmaceutical and health care regulation. He has authored and co-authored several articles relating to stem cell-based regenerative medicine and served as director of the Regenerative Medicine Foundation, where he has played various roles in connection with the annual World Stem Cell Summit. He also serves as an adjunct professor at the Deane School of Law at Hofstra University, where he teaches courses on health care and how law affects the discovery, development, and commercialization of regulated medical products.